Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Prognostic Value of Measurable Residual Disease in High-Risk Myelodysplastic Syndromes with Intensive Chemotherapy Treatment: Analysis of HOVON-SAKK Studies

Blood (2023) 142 (Supplement 1): 323.

https://doi.org/10.1182/blood-2023-184703

Published: 2023

Journal Articles

Machine Learning-Based Flow Cytometry Diagnostics in Myelodysplastic Syndromes: Validation in the HOVON89 Clinical Trial (EudraCT 2008-002195-10)

Carolien Duetz, MD, Sofie Van Gassen, PhD, Theresia M. Westers, PhD, Florentien in t Hout, MDPhD, Eline Cremers, MDPhD, Canan Alhan, MD PhD, Costa Bachas, PhD, Margot F. Van Spronsen, MD, Heleen Visser-Wisselaar, Dana Chitu, Aniek O. De Graaf, PhD, Joop Jansen, PhD, Yvan Saeys, PhD, Arjan van de Loosdrecht, MD PhD

Blood (2020) 136 (Supplement 1): 10–12.

https://doi.org/10.1182/blood-2020-136719

Published: 2020

Journal Articles

Lenalidomide with or without Erythropoietin and Granulocyte-Colony Stimulating Factor Shows Efficacy in Patients with Low and Intermediate-1 Risk Myelodysplastic Syndrome with or without Del 5q, Refractory or Unlikely to Respond to Erythropoietin. Results of a HOVON89 Phase II Randomized Multicenter Study. (EudraCT 2008-002195-10)

Blood (2016) 128 (22): 224.

https://doi.org/10.1182/blood.V128.22.224.224

Published: 2016

Journal Articles

Erythroid Lineage Analysis By Flow Cytometry Is of Highly Additive Value for MDS Diagnosis: A Study on Behalf of the HOVON89 Study Group

Eline MP Cremers, MD, Theresia M Westers, PhD, Canan Alhan, MD, Claudia Cali, Heleen A Visser-Wisselaar, PhD, Dana A Chitu, PhD, Marian JPL Stevens-Kroef, PhD, Pedro Silva Coelho, MD, Edo Vellenga, MDPhD, Saskia K. Klein, MDPhD, Pierre W. Wijermans, MDPhD, Georgine E De Greef, Marie-Cecile Legdeur, MD PhD, Petra Muus, MD PhD, Gert J Ossenkoppele, MD PhD, Joop H Jansen, PhD, Arjan A Van de Loosdrecht, MD PhD

Blood (2014) 124 (21): 4667.

https://doi.org/10.1182/blood.V124.21.4667.4667

Published: 2014

Journal Articles

Validation Of a Multi-Diagnostic Approach Including Flow Cytometry To Identify Specific Risk Categories Within Low and Intermediate-1 Risk Myelodysplastic Syndromes Within a Prospective Clinical Trial: A Study On Behalf Of The HOVON89 Study Group

Eline M.P. Cremers, MD, Theresia M. Westers, PhD, Canan Alhan, MD, Claudia Cali, Heleen A. Visser-Wisselaar, PhD, Dana A Chitu, PhD, Marian J.P.L. Stevens-Kroef, PhD, Pedro Silva Coelho, MD, Edo Vellenga, MD, PhD, Saskia K. Klein, MD PhD, Pierre W. Wijermans, MD, PhD, Georgine E. de Greef, MD, PhD, Martijn R. Schaafsma, MD, PhD, M Marwijk Kooy, MD, PhD, Petra Muus, MD, PhD, Gert J. Ossenkoppele, MD PhD, Joop H. Jansen, PhD, Arjan A. van de Loosdrecht, MD, PhD

Blood (2013) 122 (21): 1521.

https://doi.org/10.1182/blood.V122.21.1521.1521

Published: 2013

Journal Articles

Flow Cytometry Is Highly Predictive In Excluding Myelodysplastic Syndromes In Patients With Indeterminable Cytopenia: A Prospective Analysis Of 316 Patients

Eline M.P. Cremers, MD, Theresia M Westers, PhD, Canan Alhan, MD, Marielle J. Wondergem, MD, Pino J. Poddighe, PhD, Claudia Cali, C.W.M. Schouten, Gert J. Ossenkoppele, MD PhD, Arjan A. Van de Loosdrecht, MD, PhD

Blood (2013) 122 (21): 1522.

https://doi.org/10.1182/blood.V122.21.1522.1522

Published: 2013

Journal Articles

Identification Of Chromosomal Abnormalities By Microarray-Based Genomic Profiling As Compared To Karyotyping In Patients With Low and Intermediate-1 Risk Myelodysplastic Syndromes Within a Prospective Clinical Trial: A Study On Behalf Of The HOVON89 Study Group

Marian J.P.L. Stevens-Kroef, PhD, Annet Simons, Najat El Idrissi-Zaynoun, Bert A. van der Reijden, Eline M.P. Cremers, MD, Canan Alhan, Theresia M. Westers, Heleen A. Visser-Wisselaar, PhD, Dana Chitu, Edo Vellenga, S. K. Klein, Pierre W. Wijermans, MD, Georgine E. De Greef, Martyn R. Schaafsma, M. van Marwijk Kooy, Petra Muus, Gert J. Ossenkoppele, Arjan A. van de Loosdrecht, Joop H. Jansen, PhD

Blood (2013) 122 (21): 1338.

https://doi.org/10.1182/blood.V122.21.1338.1338

Published: 2013

Journal Articles

A Five Parameter Based Flow Cytometric Scoring System Refines the Revised International Prognostic Scoring System for Myelodysplastic Syndromes

Canan Alhan, MD, Theresia M. Westers, PhD, Eline M.P. Cremers, Claudia Cali, Gert J Ossenkoppele, MD, PhD, Arjan A. van de Loosdrecht, MD, PhD

Blood (2012) 120 (21): 3849.

https://doi.org/10.1182/blood.V120.21.3849.3849

Published: 2012

Journal Articles

Treatment with Lenalidomide in Myelodysplastic Syndromes with 5q Deletion; Results From the Patient Named Program (PNP) in the Netherlands

Imane Abouyahya, Canan Alhan, MD, Theresia M Westers, PhD, Jan Koedam, Gert Ossenkoppele, MD, PhD, Arjan A. Van de Loosdrecht, MD, PhD

Blood (2011) 118 (21): 5032.

https://doi.org/10.1182/blood.V118.21.5032.5032

Published: 2011

Journal Articles

Platelet Doubling After the First Azacitidine Cycle Is a Promising Predictor for Response in MDS, CMML and AML Patients in the Dutch Azacitidine Compassionate Patient Named Program,

Blood (2011) 118 (21): 3841.

https://doi.org/10.1182/blood.V118.21.3841.3841

Published: 2011

Journal Articles

Validation of a Flow Cytometric Scoring System for the Prognostication of the Myelodysplastic Syndromes: a Retrospective Cohort Study

Canan Alhan, MD, Theresia M. Westers, PhD, Claudia Cali, Gert J. Ossenkoppele, MD, PhD, Arjan A. Van de Loosdrecht, MD, PhD

Blood (2010) 116 (21): 4012.

https://doi.org/10.1182/blood.V116.21.4012.4012

Published: 2010

Journal Articles

Flow Cytometric Score Correlates with Clinical Response to Azacitidine In Intermediate-2 and High Risk Myelodysplastic Syndrome Patients

Canan Alhan, MD, Theresia M. Westers, PhD, Corien Eeltink, Claudia Cali, Gert J. Ossenkoppele, MD, PhD, Arjan A. Van de Loosdrecht, MD, PhD

Blood (2010) 116 (21): 441.

https://doi.org/10.1182/blood.V116.21.441.441

Published: 2010

Journal Articles

Immunomodulatory Effects of Azacitidine Treatment In High Risk Myelodysplastic Syndrome

Hetty J Bontkes, Canan Alhan, Corien Eeltink, Theresia M. Westers, PhD, Gert J. Ossenkoppele, MD, PhD, Arjan A. Van de Loosdrecht, MD, PhD

Blood (2010) 116 (21): 1860.

https://doi.org/10.1182/blood.V116.21.1860.1860

Published: 2010

Journal Articles

Decreased Expression of CD62L and CD54 Correlates with Poor Cytogenetic Risk Group In Myelodysplastic Syndromes

Canan Alhan, MD, Theresia M. Westers, PhD, Claudia Cali, Floortje L. Kessler, Monique Terwijn, Gert J. Ossenkoppele, MD, PhD, Sonja Zweegman, Arjan A. Van de Loosdrecht, MD, PhD

Blood (2010) 116 (21): 2915.

https://doi.org/10.1182/blood.V116.21.2915.2915

Published: 2010

Journal Articles

Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatment

Theresia M. Westers, Canan Alhan, Martine E. D. Chamuleau, Maurice J. D. L. van der Vorst, Corien Eeltink, Gert J. Ossenkoppele, Arjan A. van de Loosdrecht

Blood (2010) 115 (9): 1779–1784.

https://doi.org/10.1182/blood-2009-08-239749

Published: 2010

Includes: Supplemental data

Journal Articles

CD38 Expression On CD34+ Cells as a Single Flow Cytometric Parameter to Distinguish Myelodysplastic Syndromes (MDS) From Non-Clonal Cytopenias.

Canan Alhan, MD, Theresia M Westers, PhD, Claudia Cali, Gert J Ossenkoppele, MD, PhD, Arjan A van de Loosdrecht, MD, PhD

Blood (2009) 114 (22): 2783.

https://doi.org/10.1182/blood.V114.22.2783.2783

Published: 2009

Journal Articles

Aberrant Phenotype of Stem Cells as Assessed by Flow Cytometry Discriminates Between Low and High Risk Myelodysplastic Syndromes and Might Be Instrumental in Predicting Leukemic Evolution.

Theresia M Westers, PhD, Canan Alhan, MD, Monique Terwijn, Claudia Cali, Yvonne FCM van der Veeken, Gerrit Jan Schuurhuis, PhD, Gert J Ossenkoppele, MD, PhD, Arjan A van de Loosdrecht, MD, PhD

Blood (2009) 114 (22): 3798.

https://doi.org/10.1182/blood.V114.22.3798.3798

Published: 2009

Journal Articles

Expression of C-Type Lectin-Like Molecule-1 (CLL-1) on Stem Cells Might Discriminate De Novo Acute Myeloid Leukemia from Acute Myeloid Leukemia Originating from Myelodysplastic Syndromes

Theresia M Westers, PhD, Monique Terwijn, MSc, Canan Alhan, MD, Yvonne FCM van der Veeken, Claudia Cali, Angele Kelder, Anna van Rhenen, MD, PhD, Gerrit Jan Schuurhuis, PhD, Gert J Ossenkoppele, MD, PhD, Arjan A van de Loosdrecht, MD, PhD

Blood (2008) 112 (11): 2697.

https://doi.org/10.1182/blood.V112.11.2697.2697

Published: 2008

Journal Articles

Quantitative Dynamics of Flow Cytometric Aberrancies during Treatment with Erythropoietin/G-CSF Are Predictive for Responses in LOW/INT-I Risk Myelodysplastic Syndromes.

Theresia M Westers, PhD, Canan Alhan, MD, Claudia Cali, Gert J Ossenkoppele, MD, PhD, Arjan A van de Loosdrecht, MD, PhD

Blood (2008) 112 (11): 1661.

https://doi.org/10.1182/blood.V112.11.1661.1661

Published: 2008

NARROW

Prognostic Value of Measurable Residual Disease in High-Risk Myelodysplastic Syndromes with Intensive Chemotherapy Treatment: Analysis of HOVON-SAKK Studies

Machine Learning-Based Flow Cytometry Diagnostics in Myelodysplastic Syndromes: Validation in the HOVON89 Clinical Trial (EudraCT 2008-002195-10)

Erythroid Lineage Analysis By Flow Cytometry Is of Highly Additive Value for MDS Diagnosis: A Study on Behalf of the HOVON89 Study Group

Validation Of a Multi-Diagnostic Approach Including Flow Cytometry To Identify Specific Risk Categories Within Low and Intermediate-1 Risk Myelodysplastic Syndromes Within a Prospective Clinical Trial: A Study On Behalf Of The HOVON89 Study Group

Flow Cytometry Is Highly Predictive In Excluding Myelodysplastic Syndromes In Patients With Indeterminable Cytopenia: A Prospective Analysis Of 316 Patients

Identification Of Chromosomal Abnormalities By Microarray-Based Genomic Profiling As Compared To Karyotyping In Patients With Low and Intermediate-1 Risk Myelodysplastic Syndromes Within a Prospective Clinical Trial: A Study On Behalf Of The HOVON89 Study Group

A Five Parameter Based Flow Cytometric Scoring System Refines the Revised International Prognostic Scoring System for Myelodysplastic Syndromes

Treatment with Lenalidomide in Myelodysplastic Syndromes with 5q Deletion; Results From the Patient Named Program (PNP) in the Netherlands

Platelet Doubling After the First Azacitidine Cycle Is a Promising Predictor for Response in MDS, CMML and AML Patients in the Dutch Azacitidine Compassionate Patient Named Program,

Validation of a Flow Cytometric Scoring System for the Prognostication of the Myelodysplastic Syndromes: a Retrospective Cohort Study

Flow Cytometric Score Correlates with Clinical Response to Azacitidine In Intermediate-2 and High Risk Myelodysplastic Syndrome Patients

Immunomodulatory Effects of Azacitidine Treatment In High Risk Myelodysplastic Syndrome

Decreased Expression of CD62L and CD54 Correlates with Poor Cytogenetic Risk Group In Myelodysplastic Syndromes

Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatment

CD38 Expression On CD34+ Cells as a Single Flow Cytometric Parameter to Distinguish Myelodysplastic Syndromes (MDS) From Non-Clonal Cytopenias.

Aberrant Phenotype of Stem Cells as Assessed by Flow Cytometry Discriminates Between Low and High Risk Myelodysplastic Syndromes and Might Be Instrumental in Predicting Leukemic Evolution.

Expression of C-Type Lectin-Like Molecule-1 (CLL-1) on Stem Cells Might Discriminate De Novo Acute Myeloid Leukemia from Acute Myeloid Leukemia Originating from Myelodysplastic Syndromes

Quantitative Dynamics of Flow Cytometric Aberrancies during Treatment with Erythropoietin/G-CSF Are Predictive for Responses in LOW/INT-I Risk Myelodysplastic Syndromes.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only